Godavari Biorefineries Limited has informed the Exchange regarding a revised press release dated July 22, 2025, titled "Revised Press Release".
GODAVARIB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Biorefineries has been granted a patent by China's patent office (CNIPA) for its novel anti-cancer molecule called HYDROXY-1,4-NAPHTHALENEDIONE. The patent is held through its clinical-stage biotech division, Sathgen Therapeutics, and covers a class of compounds shown to inhibit cancer and cancer stem cells in lab studies. The molecule has shown efficacy against breast and prostate cancer cell types. The company notes its lead molecule is currently in clinical trials and protected by global patents. The announcement also highlights the company's global presence, with exports to over 20 countries.
Positive news for shareholders as it strengthens the company's intellectual property portfolio in a major market (China) and supports its expansion into the biotech/pharma space beyond its core biofuels business. The patent adds value to Sathgen Therapeutics' pipeline but commercial returns remain distant given the molecule is still in clinical trials.